______________________________________________________________________________
Note: The following is edited from a press release from Sangamo Biosciences. Read the full press release in its entirety here.
Sangamo Biosciences presented data during the recent American Society of Hematology (ASH) Annual Meeting regarding preclinical and manufacturing data of SB-525, its gene therapy program for hemophilia A.
“We have developed an improved gene therapy vector for treatment of hemophilia A which we believe is highly competitive, and we remain on track to file an Investigational New Drug (IND) application for our clinical program by the end of 2016,” said Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo’s president and chief executive officer.
